Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2023.1090
Abstract: Importance The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in interaction with background diuretic therapy in patients with heart failure and preserved ejection fraction (HFpEF). Objective To assess the safety and efficacy of… read more here.
Keywords: ejection fraction; heart failure; emperor preserved; use ... See more keywords
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of heart failure"
DOI: 10.1002/ejhf.2857
Abstract: BACKGROUND In the EMPEROR-Preserved trial, empagliflozin improved clinical outcomes of patients with heart failure with preserved ejection fraction. In this pre-specified analysis, we aim to study the effect of empagliflozin on cardiovascular and kidney outcomes… read more here.
Keywords: emperor preserved; heart failure; without ckd; kidney ... See more keywords
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehac693
Abstract: Abstract Aims Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects.… read more here.
Keywords: emperor preserved; 130 mmhg; failure; heart ... See more keywords